Arrowhead Research Corp. (NASDAQ:ARWR) was up 3.3% on Monday . The company traded as high as $8.00 and last traded at $7.75, with a volume of 921,962 shares traded. The stock had previously closed at $7.50.

A number of equities research analysts recently weighed in on ARWR shares. Jefferies Group restated a “hold” rating and set a $4.75 price objective on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. William Blair started coverage on Arrowhead Research Corp. in a research note on Friday. They set an “outperform” rating for the company. Cantor Fitzgerald started coverage on Arrowhead Research Corp. in a research note on Wednesday, August 17th. They set a “buy” rating and a $15.00 price objective for the company. Piper Jaffray Cos. decreased their price objective on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. Finally, Chardan Capital started coverage on Arrowhead Research Corp. in a research note on Thursday, May 19th. They set a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $10.44.

The firm’s market capitalization is $467.78 million. The company’s 50 day moving average price is $5.90 and its 200-day moving average price is $5.28.

Arrowhead Research Corp. (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. The business had revenue of $39.58 million for the quarter, compared to analyst estimates of $0.05 million. During the same period last year, the business earned ($0.27) EPS. Arrowhead Research Corp.’s revenue was down 68.0% compared to the same quarter last year. On average, equities analysts predict that Arrowhead Research Corp. will post ($1.31) EPS for the current year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.